United Therapeutics (UTHR) Short term Debt (2017 - 2025)

United Therapeutics has disclosed Short term Debt across 6 years of filings, most recently posting $200.0 million for Q1 2025.

• Short term Debt for Q1 2025 came in at $200.0 million, down 50.0% year-over-year; the trailing twelve-month figure through Mar 2025 was $200.0 million (down 50.0% YoY), and the FY2024 annual result was $300.0 million, down 25.0% from the prior year.
• Short term Debt came in at $200.0 million for Q1 2025 at United Therapeutics, down from $300.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $400.0 million in Q4 2023 to a low of $200.0 million in Q1 2025.
• The 3-year median for Short term Debt is $400.0 million (2023), against an average of $342.9 million.
• Across the five-year window, Short term Debt jumped 33.33% in 2024 and plunged 50.0% in 2025, its largest moves.
• United Therapeutics' Short term Debt stood at $400.0 million in 2023, then declined by 25.0% to $300.0 million in 2024, then plunged by 33.33% to $200.0 million in 2025.
• The last three Short term Debt figures came in at $200.0 million (Q1 2025), $300.0 million (Q4 2024), and $400.0 million (Q3 2024), per Business Quant data.